Arthur Obel

Last updated

Professor Arthur Obel, a Kenyan scientist, identified the first cases of Human Immunodeficiency Virus in Kenya and treated many AIDS patients. [1] He developed two medications, Kemron and Pearl Omega, to cure HIV/AIDS. [2] It was later discovered that neither Kemron nor Pearl Omega were effective medications against the retrovirus. [2]

Contents

Education, career, and honoraries

Education

Professor Arthur Obel received his PhD in Therapeutics from the London University in 1978. He then received his M.D. in Clinical Medicine from the University of Nairobi in 1987. [3]

Career

Dr. Obel was head of the Public Administration of the Kenya Institute of Administration in 1990. He also had the position of Chief Research Officer of the Kenya Medical Research Institute (KEMRI) from 1989 to 1991. Obel later became the Chief Scientist of the Office of the President of Kenya from 1995 to 1999. [3] This high position in government allowed him to attain many funds for his research. Being in a respectable position also allowed him to have many close friends that were high ranking government officials, such as Philip Mbithi, the former Chief Secretary in the Office of the President of Kenya. [2]

Honoraries

Professor Obel received many honoraries. He was a member of the Global Epidemiology Society in 1983 and the Achievers Society in 1983. Obel did a fellowship with numerous institutions including the Jewish Chemists Federation in 1986, the International Diabetes Federation in 1986, and the Global Pharmaceutical Federation in 1987. He was also a Project Management Professional (PMP) with the Centre for Finance and Project Management in 2004. [3]

Kemron

Dr. Arthur Obel claimed that Kemron and Pearl Omega were the cures for HIV/AIDS. [2]

Professor Obel joined KEMRI, the Kenya Medical Research Institute, where they aimed to find an effective treatment to eradicate HIV/AIDS. [1] KEMRI and Obel picked up a medication that was developed but denied approval for testing in the United States and lowered the concentration before testing. This medication was Kemron. [1] The medication was tested in other areas, such as the University of Makerere. It was then discovered that Kemron did nothing much to help with the disease. [2] Kemron only reversed the symptoms of the HIV disease for a short period of time. Because of this, people were quick to purchase the expensive medication. Dr. Obel received much backlash because of this and resigned from KEMRI in January 1991. [1]

Pearl Omega

Pearl Omega, a herb, was found to have very few positive outcomes when combatting HIV. [2] Obel claimed that Pearl Omega was a protease inhibitor and sold the drug at a very expensive price. [1] One bottle of Pearl Omega was KSh.  30,000/=, the equivalent of £350  stg. [4] Human trials of this medication started in 1991 and Obel claimed that the medication restored the health of seven AIDS patients. [4] However, there was no scientific data to back up his claims. [4] People were much less inclined to purchase the second drug produced by Obel after Kemron. The Health Minister disowned the drug and many institutions banned the use of the drug after the discrediting of Obel. Pearl Omega was later found to be sold in the black market illegally as it is illegal for any medication to be sold before it is approved by the Health Minister in Kenya. [4]

Aftermath of Kemron and Pearl Omega

Professor Obel was sued by many patients because of Kemron and Pearl Omega's ineffectiveness [2] and he later had a court case versus the Kenya AIDS Society in 1998. [5] This court case against Obel was because he manufactured, distributed, and sold Pearl Omega without the approval of the Health Minister of Kenya. [5] Obel won the case and gained a reputation of falsifying information and fraud.

Professor Arthur Obel continued his work on HIV/AIDS even after the discreditation of the Kemron and Pearl Omega medications. In 2011, he published work on the correlation of WHO clinical staging with CD4 cell count in adult HIV positive patients at the Kenyatta National Hospital. [3]

Obel wrote a book called "Curbing the HIV/AIDS Menace Effectively" in 1995.

Work not relating to HIV/AIDS

Although Obel is most known for his work on Kemron and Pearl Omega, a big part of Dr. Obel's research consisted of practical therapeutics. He has numerous published works including practical therapeutics on antibiotic therapy, the use of insulin, the use of anti-diabetic agents, the treatment of gout, the treatment of peptic ulcers, anxiolytic drugs, and the therapy of diarrhoeal diseases. [3]

Professor Obel also has written, and self-published, numerous books such as "Power and Intrigue," a book relating to one's power, whether it be associative, personal, professional, or reward power, "Kenya's Industrialization Strategy," and "Resilient Manhood Dynamism: The Basis of a Rapid Take-off."

Related Research Articles

<span class="mw-page-title-main">Beckman Research Institute</span> American medical research institute founded 1984

The Beckman Research Institute of City of Hope (BRI) is a not-for-profit medical research facility located at and partnering with the City of Hope National Medical Center in Duarte, California, United States. It is dedicated to studying normal and abnormal biological processes which may be related to cancer, diabetes, HIV/AIDS and other life-threatening diseases. Both basic and clinical research are carried out in cooperation with the City of Hope National Medical Center. The institute itself is organized into more than 20 departments and divisions. As of 2021, the director is Steven T. Rosen. The Beckman Research Institute also hosts the Irell & Manella Graduate School of Biological Sciences whose founding dean was Arthur Riggs.

The management of HIV/AIDS normally includes the use of multiple antiretroviral drugs as a strategy to control HIV infection. There are several classes of antiretroviral agents that act on different stages of the HIV life-cycle. The use of multiple drugs that act on different viral targets is known as highly active antiretroviral therapy (HAART). HAART decreases the patient's total burden of HIV, maintains function of the immune system, and prevents opportunistic infections that often lead to death. HAART also prevents the transmission of HIV between serodiscordant same-sex and opposite-sex partners so long as the HIV-positive partner maintains an undetectable viral load.

<span class="mw-page-title-main">Gilead Sciences</span> American pharmaceutical company

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100.

Matthias Rath is a doctor, businessman, and vitamin salesman. He earned his medical degree in Germany. Rath claims that a program of nutritional supplements, including formulations that he sells, can treat or cure diabetes, cardiovascular disease, cancer, and HIV/AIDS. These claims are not supported by any reliable medical research. Rath runs the Dr. Rath Health Foundation, has been closely associated with Health Now, Inc., and founded the Dr. Rath Research Institute.

<span class="mw-page-title-main">Fereydoon Batmanghelidj</span> Iranian naturopath (1931–2004)

Fereydoon Batmanghelidj was an Iranian doctor, naturopath, HIV/AIDS denialist and writer. He is best known for believing increased water consumption is the cure for most disease, a view not supported by clinical evidence and considered quackery by medical experts.

<span class="mw-page-title-main">Joep Lange</span> Dutch clinical researcher (1954–2014)

Joseph Marie Albert "Joep" Lange was a Dutch clinical researcher specialising in HIV therapy. He served as the president of the International AIDS Society from 2002 to 2004. He was a passenger on Malaysia Airlines Flight 17, which was shot down on 17 July 2014 over Ukraine.

The Kenya Medical Research Institute (KEMRI) is a state corporation established through the Science and Technology (Amendment) Act of 1979,, during the tenure of Nicholas Biwott as Minister of State, as the national body responsible for carrying out health research in Kenya.

<span class="mw-page-title-main">Health in Kenya</span> Health status and problems in Kenya

Tropical diseases, especially malaria and tuberculosis, have long been a public health problem in Kenya. In recent years, infection with the human immunodeficiency virus (HIV), which causes acquired immune deficiency syndrome (AIDS), also has become a severe problem. Estimates of the incidence of infection differ widely.

The Dr. Paul Janssen Award for Biomedical Research is given annually by Johnson & Johnson to honor the work of an active scientist in academia, industry or a scientific institute in the field of biomedical research. It was established in 2004 and perpetuates the memory of Paul Janssen, the founder of Janssen Pharmaceutica, a Johnson & Johnson subsidiary.

Initial events and trends in the discussion of HIV and AIDS in mass media contributed to the stigma and discrimination against those affected with the disease. Later discussion, sometimes led by HIV+ individuals themselves, moved toward advocacy and education on disease prevention and management. The UNESCO report on Journalism Education says, "Well researched television content can create public awareness about HIV prevention, treatment, care and support can potentially influence the development and implementation of relevant policies."

Kemron is the name of a drug which was released in Kenya in 1991 and was alleged to be highly effective in removing the symptoms of AIDS. When put under international scrutiny, the treatment was seen to perform no better than placebo. The advent of the drug was notable for the government support and international attention it received.

Julio S. G. Montaner is an Argentine-born Canadian physician, professor and researcher. He is the director of the British Columbia Centre for Excellence in HIV/AIDS, the chair in AIDS Research and head of the Division of AIDS in the Faculty of Medicine at the University of British Columbia and the past-president of the International AIDS Society. He is also the director of the John Ruedy Immunodeficiency Clinic, and the Physician Program Director for HIV/AIDS PHC. He is known for his work on HAART, a role in the discovery of triple therapy as an effective treatment for HIV in the late 1990s, and a role in advocating the "Treatment as Prevention" Strategy in the mid-2000s, led by Myron Cohen of the HPTN 052 trial.

Deborah Persaud is a Guyanese-born American virologist who primarily works on HIV/AIDS at Johns Hopkins Children's Center.

Big Pharma conspiracy theories are conspiracy theories that claim that pharmaceutical companies as a whole, especially big corporations, act in dangerously secretive and sinister ways that harm patients. This includes concealing effective treatments, perhaps even to the point of intentionally causing and/or worsening a wide range of diseases, in the pursuit of higher profits and/or other nefarious goals. The general public supposedly lives in a state of ignorance, according to such claims.

Roy D. Mugerwa was a Ugandan physician, cardiologist and researcher. His contribution to the world of academics include being a Professor Emeritus at Makerere University College of Health Sciences in Kampala, cardiology in Uganda, researching HIV/AIDS and tuberculosis, and his efforts to find an effective HIV vaccine.

<span class="mw-page-title-main">Robert T. Schooley</span> American infectious disease physician

Robert "Chip" T. Schooley is an American infectious disease physician, who is the Vice Chair of Academic Affairs, Senior Director of International Initiatives, and Co-Director at the Center for Innovative Phage Applications and Therapeutics (IPATH), at the University of California San Diego School of Medicine. He is an expert in HIV and hepatitis C (HCV) infection and treatment, and in 2016, was the first physician to treat a patient in the United States with intravenous bacteriophage therapy for a systemic bacterial infection.

Elizabeth Anne Bukusi FAAS is a research professor working within the field of obstetrics and gynaecology, and global health. Bukusi's main areas of research focus around sexually transmitted infections, women's health, reproductive health, and HIV care, prevention and treatment. Bukusi is the Chief Research Officer at the Kenya Medical Research Institute (KEMRI) and led a "landmark" study on the use of PrEP in Kenya.

<span class="mw-page-title-main">Davy Kiprotich Koech</span> Kenyan scientist (1951–2024)

Davy Kiprotich Koech was a Kenyan scientist. He was the Chief Executive Officer Centre for Clinical & Molecular Sciences; Professor of Immunology & Molecular Medicine; Distinguished Professor, The Australian-Asian Institute of Civil Leadership.

Trudie Lang is a Professor of Global Health Research at the University of Oxford. She specialises in clinical trials research capacity building in low-resource setting, and helped to organise the trial for the drug brincidofovir during the 2014 Ebola virus outbreak.

Karithi Ruth Wanjiru Nduati is a Kenyan Pediatrician and Epidemiologist who also teaches at the University of Nairobi College of Health Sciences. She is also currently leading an interdisciplinary program through the University of Nairobi School of Medicine to educate physician-researchers to best implement HIV treatment and prevention methods backed by research. The program was funded by the Fogarty Training Grant which is a part of the PEPFAR funds the country of Kenya received.

References

  1. 1 2 3 4 5 Iliffe, John (1998). East African Doctors: A History of the Modern Profession. Cambridge University Press. pp. 220–243.
  2. 1 2 3 4 5 6 7 R, Dodd (1996-06-15). "Patients Sue "AIDS-cure" Kenyan Scientist". Lancet. 347 (9016): 1688. doi:10.1016/s0140-6736(96)91516-0. PMID   8642971. S2CID   25730611 . Retrieved 2020-06-07.
  3. 1 2 3 4 5 "University of Nairobi Personal Websites". University of Nairobi Personal Websites. Retrieved 2020-06-07.
  4. 1 2 3 4 "'Hoax' Aids cure makes a fortune for Kenyan coterie". The Independent. 1996-06-03. Retrieved 2020-06-22.
  5. 1 2 "civ app 188 of 97 - Kenya Law". kenyalaw.org. Retrieved 2020-06-14.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.